Home > Healthcare > Biotechnology > Bioservices > Personalized Medicine Biomarkers Market

Personalized Medicine Biomarkers Market Trends

Report ID: GMI12082
Published Date: Oct 2024
Report Format: PDF

Download Free Sample

Personalized Medicine Biomarkers Market Trends

Advances in genomics and proteomics significantly drive growth in the market by enhancing the precision of disease profiling. Genomic technologies, such as next-generation sequencing, reveal genetic mutations that can predict disease susceptibility and treatment responses, while proteomics identifies protein-level changes linked to various disease states. These technologies enable the discovery of specific biomarkers, allowing for targeted therapies that increase treatment efficacy and reduce side effects. This shift toward precise, patient-specific care is crucial for managing complex diseases like cancer and autoimmune disorders, fueling demand for biomarker-driven diagnostics and treatments and fostering a patient-centered approach to healthcare.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global personalized medicine biomarkers industry was valued at USD 15.9 billion in 2023 and is estimated to grow at a CAGR of over 15.1% from 2024 to 2032, driven by the rising incidence of chronic diseases and advancements in genomics and proteomics.

The genomic biomarkers segment dominated the market with USD 6.6 billion in 2023, playing a pivotal role in disease detection, risk assessment, and treatment optimization.

U.S. personalized medicine biomarkers industry is expected to grow at a 15% CAGR, reaching USD 21.1 billion by 2032, led by advanced healthcare infrastructure and substantial R&D investments.

Key players in the industry include Abbott Laboratories, Bio-Rad Laboratories, Danaher, EKF Diagnostics Holdings, F. Hoffmann-La Roche, Illumina, Lifesign, Merck, Myriad Genetics, QIAGEN, Signosis, and Singulex.